Objective—To determine clinical signs, diagnostic
findings, outcome, and prognostic factors in dogs
treated surgically for massive hepatocellular carcinoma
(HCC) and compare survival times of surgically
and conservatively treated dogs.
Procedure—Medical records were examined for clinical
signs, diagnostic and surgical findings, and postoperative
outcome. Dogs were allocated into surgery
and nonsurgery groups depending on whether curative-
intent liver lobectomy was performed. Data from
the surgical and nonsurgical groups were analyzed to
identify prognostic factors and determine and compare
rates of tumor control and survival time.
Results—42 dogs were treated surgically, and 6 were
managed conservatively. In the surgery group, intraoperative
mortality rate was 4.8% with no local recurrence,
metastatic rate was 4.8%, and median survival
time was > 1,460 days (range, 1 to 1,460 days). High
alanine aminotransferase and aspartate aminotransferase
activities were associated with poor prognosis.
Median survival time for the nonsurgery group was
270 days (range, 0 to 415 days), which was significantly
less than that of surgically treated dogs.
Conclusions and Clinical Relevance—Liver lobectomy
is recommended for dogs with massive HCC
because tumor-related mortality rate was 15.4 times
higher in dogs in the nonsurgery group, compared
with the surgery group. Tumor control was excellent
after surgical resection with no local recurrence and a
low metastatic rate. Prognostic factors were identified,
but their clinical relevance was uncertain
because only 9.5% of dogs in the surgery group died
as a result of their disease. (J Am Vet Med Assoc